Table 2.
DU90% in Queensland and in Australia for the overall NSAID utilization in Concession beneficiaries between 1997 and 2003
| Australia DU90% | ||||
| 1997–1999% | 2000% | 2001% | 2002% | 2003% |
| Naproxen* 28 | Celecoxib+ 35 | Celecoxib+ 40 | Celecoxib+ 39 | Celecoxib+ 35 |
| Diclofenac** 21 | Naproxen* 20 | Rofecoxib+ 16 | Rofecoxib+ 22 | Rofecoxib+ 25 |
| Ketoprofen# 16 | Diclofenac** 15 | Naproxen* 16 | Naproxen* 12 | Diclofenac** 12 |
| Piroxicam# 10 | Ketoprofen# 9 | Diclofenac** 14 | Diclofenac** 12 | Naproxen* 11 |
| Indomethacin* 7 | Piroxicam# 7 | Ketoprofen# 7 | Ketoprofen# 5 | Meloxicam+ 9 |
| Ibuprofen** 6 | Ibuprofen** 5 | |||
| Queensland DU90% | ||||
| 1997–1999% | 2000% | 2001% | 2002% | 2003% |
| Naproxen* 27 | Celecoxib+ 45 | Celecoxib+ 43 | Celecoxib+ 40 | Celecoxib+ 35 |
| Diclofenac** 20 | Naproxen* 14 | Rofecoxib+ 16 | Rofecoxib+ 22 | Rofecoxib+ 26 |
| Ketoprofen# 17 | Diclofenac** 13 | Naproxen* 10 | Diclofenac** 9 | Diclofenac** 9 |
| Piroxicam# 12 | Ketoprofen# 8 | Diclofenac** 10 | Naproxen* 9 | Meloxicam+ 8 |
| Ibuprofen** 9 | Ketoprofen# 5 | Ibuprofen** 5 | Naproxen* 8 | |
| Indomethacin* 5 | Ibuprofen** 5 | Ketoprofen# 4 | Ibuprofen** 5 | |
| + Cox-2 inhibitors | ** ns-NSAIDs low risk | # ns-NSAIDs high risk | * ns-NSAIDs moderate risk | |